Alkermes plc

ALKS

$29.33

Name : Alkermes plc

Sector : Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Mark. Cap: $4,842,896,384.00

EPSttm : 2.01

Alkermes plc

$29.33

1.00%

$0.29

Float Short %

9.87

Margin Of Safety %

-1

Put/Call OI Ratio

0.4

EPS Next Q Diff

-0.11

EPS Last/This Y

-0.29

EPS This/Next Y

0.39

Price

29.33

Target Price

43.88

Analyst Recom

1.44

Performance Q

1.66

Relative Volume

1.22

Beta

0.5

Ticker: ALKS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	ALKS	30.98	0.44	1.21	13116
2025-10-21	ALKS	31.46	0.44	1.35	13248
2025-10-22	ALKS	31.09	0.48	1.34	14507
2025-10-23	ALKS	30.04	0.49	7.10	14682
2025-10-24	ALKS	29.8	0.51	4.10	14884
2025-10-27	ALKS	29.74	0.52	0.45	14970
2025-10-28	ALKS	31.03	0.51	0.08	15025
2025-10-29	ALKS	31.44	0.46	0.10	16364
2025-10-30	ALKS	30.82	0.44	0.11	16967
2025-10-31	ALKS	30.7	0.44	0.82	17138
2025-11-03	ALKS	30.18	0.44	3.36	17140
2025-11-04	ALKS	30.38	0.45	1.59	17275
2025-11-05	ALKS	31.03	0.45	0.24	17317
2025-11-06	ALKS	31.68	0.46	0.13	17472
2025-11-07	ALKS	32.9	0.45	0.05	17547
2025-11-10	ALKS	32.65	0.42	1.35	18653
2025-11-11	ALKS	33.81	0.43	0.13	18904
2025-11-12	ALKS	31.39	0.41	1.75	19740
2025-11-13	ALKS	31.03	0.44	1.56	20631
2025-11-14	ALKS	29.03	0.44	0.17	20673
2025-11-17	ALKS	29.33	0.40	0.09	23442
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	ALKS	30.98	-47.3	-87.5	1.71
2025-10-21	ALKS	31.45	-47.3	-90.9	1.71
2025-10-22	ALKS	31.09	-47.3	-99.2	1.72
2025-10-23	ALKS	30.04	-47.3	-108.1	1.72
2025-10-24	ALKS	29.79	-47.1	-98.0	1.76
2025-10-27	ALKS	29.73	-47.1	-95.6	1.76
2025-10-28	ALKS	31.00	-47.1	-77.2	1.76
2025-10-29	ALKS	31.43	-47.1	-88.9	1.76
2025-10-30	ALKS	30.82	-59.4	-87.3	1.95
2025-10-31	ALKS	30.70	-59.4	-72.4	1.95
2025-11-03	ALKS	30.18	-59.4	-85.9	1.95
2025-11-04	ALKS	30.40	-59.4	-76.1	1.95
2025-11-05	ALKS	31.07	-59.4	-69.9	1.95
2025-11-06	ALKS	31.67	-59.4	-71.3	1.95
2025-11-07	ALKS	32.89	-59.4	-63.6	1.95
2025-11-10	ALKS	32.65	-59.4	-82.2	1.95
2025-11-11	ALKS	33.81	-59.4	-64.6	1.95
2025-11-12	ALKS	31.40	-59.4	-107.8	1.95
2025-11-13	ALKS	30.99	-59.4	-84.5	1.95
2025-11-14	ALKS	29.02	-59.4	-105.4	1.95
2025-11-17	ALKS	29.33	-61.7	-74.8	1.93
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	ALKS	-0.38	-2.09	9.45
2025-10-21	ALKS	-0.38	-2.09	9.45
2025-10-22	ALKS	-0.38	-2.09	9.45
2025-10-23	ALKS	-0.38	-2.09	9.45
2025-10-24	ALKS	-0.38	-2.09	9.45
2025-10-27	ALKS	-0.38	-1.05	8.94
2025-10-28	ALKS	-0.38	-1.05	8.94
2025-10-29	ALKS	-0.38	-1.05	8.94
2025-10-30	ALKS	-0.38	-1.05	8.94
2025-10-31	ALKS	-0.38	-1.05	8.94
2025-11-03	ALKS	-0.60	-1.52	8.94
2025-11-04	ALKS	-0.60	-1.52	8.94
2025-11-05	ALKS	-0.60	-1.52	8.94
2025-11-06	ALKS	-0.60	-1.52	8.94
2025-11-07	ALKS	-0.60	-1.52	8.94
2025-11-10	ALKS	-0.60	-1.27	8.94
2025-11-11	ALKS	-0.60	-1.27	8.94
2025-11-12	ALKS	-0.60	-1.27	9.87
2025-11-13	ALKS	-0.60	-1.27	9.87
2025-11-14	ALKS	-0.60	-1.27	9.87
2025-11-17	ALKS	-0.61	0.64	9.87
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.49

Avg. EPS Est. Current Quarter

0.4

Avg. EPS Est. Next Quarter

0.38

Insider Transactions

-0.61

Institutional Transactions

0.64

Beta

0.5

Average Sales Estimate Current Quarter

378

Average Sales Estimate Next Quarter

378

Fair Value

29.15

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

19.5

Max Drawdown 5-Year %

-33.2

Target Price

43.88

P/E

14.51

Forward P/E

17.75

PEG

P/S

3.18

P/B

2.79

P/Free Cash Flow

9.87

EPS

2.02

Average EPS Est. Cur. Y

1.93

EPS Next Y. (Est.)

2.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.27

Relative Volume

1.22

Return on Equity vs Sector %

-7.4

Return on Equity vs Industry %

12.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.21

EBIT Estimation

-74.8

Alkermes plc

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

stock quote shares ALKS – Alkermes plc Stock Price stock today

news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ALKS – Alkermes plc yahoo finance google finance

stock history ALKS – Alkermes plc invest stock market

stock prices ALKS premarket after hours

ticker ALKS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALKS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y